Echtzeit-Aktienkurs TRACON PHARMACEUT.DL-,001
Bid:
Ask:
Echtzeit-Chart der TRACON PHARMACEUT.DL-,001 Aktie
Fundamentaldaten der TRACON PHARMACEUT.DL-,001 Aktie
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2018 [USD] | 3,00 Mio. | -34,96 Mio. | -34,96 Mio. | -1,30 | - | - | - |
| 2017 [USD] | 8,76 Mio. | -19,10 Mio. | -19,10 Mio. | -1,14 | - | - | - |
| 2016 [USD] | 3,45 Mio. | -27,01 Mio. | -27,01 Mio. | -2,13 | - | - | - |
| 2015 [USD] | 7,90 Mio. | -24,41 Mio. | -24,44 Mio. | -2,20 | - | - | - |
| 2014 [USD] | 3,60 Mio. | -6,81 Mio. | -7,11 Mio. | -4,40 | - | - | - |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. |
Profil der TRACON PHARMACEUT.DL-,001 Aktie
TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. The company products include TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types, TRC205 an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. TRACON Pharmaceuticals was founded in October 2004 and is headquartered in San Diego, CA.